MTOR and neuroendocrine carcinoma: Neuroendocrine tumors from small cell lung and colorectal cancers also display an enhanced sensitivity to mTOR pathway inhibition, indicating that the phenomenon may apply more broadly to other neuroendocrine cancers.21, 22, 23